You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Automated, portable, concurrent, WMD detection system

    SBC: Concurrent Analytical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is the development of a fully automated, wireless ethernet capable, near realtime, field deployable immunoassay-based analysis system for the concurrent, ultra low-level detection of biowarfare agents in air or water by using innovations in surface enhanced Raman scattering (SERS) and related supporting materials and hardware. A ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. Discovery of Anti-Bioweapon Agents in BAC Libraries

    SBC: EMETAGEN, LLC.            Topic: N/A

    DESCRIPTION (provided by applicant): Antibiotics are an essential component in bio-defense preparedness. Soil microorganisms were a major source of antibiotics during the 20th century, yet antibiotic discovery is now severely limited. A primary reason is that drug discovery from microorganisms has been confined to those microbes that can be recovered by laboratory cultivation, yielding high rates ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  3. Detecting Early Emerging Drug-Resistant HIV Populations

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Treatment of human immunodeficiency virus type 1 (HIV) infection with antiretroviral agents invariably leads to selection and accumulation of drug-resistant mutants that arise due to the intrinsically low fidelity of HIV polymerase. Early detection of these growing variants may be clinically relevant. Before the level of clinical importance can be ascertained, ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Pharmacophylogenomic Dates for the Master Catalog

    SBC: ERAGEN BIOSCIENCES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This project will enhance the MASTERCATALOG, EraGen's product that combines an evolutionarily organized protein sequence database with tools to enable phylogenomics analysis. This will help maintain the commercial advantage of the MASTERCATALOG over public databases and tools, and help ensure that the MASTERCATALOG continues to enjoy its status as the "best in ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. POSITRON EMISSION TOMOGRAPHY GUIDED PROSTATE BIOPSY

    SBC: I.SOLUTIONS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Prostate cancer imaging with positron emission tomography (PET) has been facilitated by the recent development of the radioactive tracer fluorine-18 fluorocholine (F-18 FCH). Like other substrates for the enzyme choline kinase, F-18 FCH demonstrates increased accumulation in malignant cells. In addition to whole-body cancer staging, F-18 FCH PET may potentia ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  6. Development of Plant Derived Antibodies for Drugs Abuse

    SBC: INTERVEXION THERAPEUTICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this combination Phase I / Phase II STTR project is to test the hypothesis that anti-drug monoclonal antibodies are a safe and effective therapy for the medical problems associated with phencyclidine (PCP) abuse. There are currently no specific medications for treating the medical problems caused by acute or chronic PCP abuse. Thus, long-lasting ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Natural feedstocks for diversity oriented synthesis

    SBC: Promiliad Biopharma Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): This STTR application requests funds to support the transfer of specific synthetic expertise and methodologies from the Wright Group at Dartmouth College to investigators at Promiliad Biopharma in an effort to reduce Promiliad's REBACS strategy to the level of practice. These efforts will focus on the use of a high-complexity feedstock, nonactic acid, as the p ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  8. Endogenous Retrovirus Herv-K in Lymphoma and ALS

    SBC: SLIL BIOMEDICAL CORPORATION            Topic: N/A

    DESCRIPTION (provided by investigator): Retroviruses have long been associated with both hematological malignancies and neurological disorders in humans. Infection with the retrovirus HTLV-1 can lead either to the development of adult T cell leukemia (ATL) or HTLV-1 associated myelopathy. Infection with HIV is associated with the development of Non- Hodgkin's lymphoma (NHL) and the development of ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Antimicrobial Human Skin Substitute

    SBC: Stratatech Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to genetically engineer a therapeutic human skin substitute for use in the treatment of skin lesions such as skin wounds (e.g., pathological or traumatic) and ulcers (e.g., venous and diabetic ulcers). Chronic skin ulcers are particularly problematic as they typically become infected resulting in impaired wound healing an ...

    STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Efficacy of Liposomal Budesonide in Experimental Asthma

    SBC: VGSK, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Asthma is the most common chronic illness in childhood and affects 5 to 10% of the population. The disease is characterized by acute bronchoconstriction, chronic inflammation, and airway remodeling which may lead to progressive, irreversible lung damage. Current asthma therapy is directed at reducing the lung inflammation with the use of anti-inflammatory drugs ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government